Last reviewed · How we verify
Drug: GC4419 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Drug: GC4419 (Drug: GC4419) — Galera Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Drug: GC4419 TARGET | Drug: GC4419 | Galera Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Drug: GC4419 CI watch — RSS
- Drug: GC4419 CI watch — Atom
- Drug: GC4419 CI watch — JSON
- Drug: GC4419 alone — RSS
Cite this brief
Drug Landscape (2026). Drug: GC4419 — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-gc4419. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab